• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

FAQ’s: Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy

April 2, 2016 By Dr. Jeremy Feldman

Your Questions Answered.

Our readers have submitted some great questions.  We value your questions and encourage you to continue to tell us about your interests and questions.

What is happening with the implanted Remodulin Pump?

The FDA recently announced they are not ready to approve the implanted pump system for the delivery of continuously infused Remodulin.  They are asking that more work be done prior to approving the system.  Many patients across the United States have been eagerly awaiting approval of the implanted system.  Medtronic and United Therapeutics continue to work to bring this important treatment to patients.  No timeline has been released.

Is a right heart catheterization necessary to diagnose pulmonary arterial hypertension?

Internal anatomy of the pulmonary arteriesThe emphatic answer is absolutely.  If your physician wants to diagnose you as having pulmonary arterial hypertension without performing a right heart catheterization then you would be best served by seeking a more expert opinion.

While an echocardiogram may point to the diagnosis, it is never enough to make a firm diagnosis or initiate treatment.

The Pulmonary Hypertension Association has developed a center of excellence label “Comprehensive Care Center” that has been awarded to more than 30 programs across the country.  These programs have a demonstrated track record of outstanding care in all aspects of PAH.

We received a question about PAH and pregnancy

Pregnancy is very dangerous for women with PAH.  Depending on the severity of a woman’s PAH, mortality may be as high as 50%.  As a woman moves through the first trimester of pregnancy the blood volume increases by about 50%, peaking in the third trimester.  In patients with PAH, the weakened right ventricle is unable to accommodate the increased blood volume and may further decline.  This results in worsening right heart failure.  A second period of great risk involves delivery.

PAH patient storyLastly, in the first week after delivery there is a process where edema fluid moves back into the blood vessels and results in rapid increases in blood volume.  This can precipitate abrupt right heart failure.  Adding to the risk of pregnancy is that all endothelin receptor antagonists are 100% contraindicated in pregnancy due to risk of birth defects.  Any woman with PAH who is pregnant should immediately be seen by a high-risk obstetrician and a PAH expert at a center of excellence.

Filed Under: Living with PAH

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

Dr. Jeremy Feldman PAH Specialist

Why I Am A Pulmonary Hypertension Specialist

By Dr. Jeremy Feldman

November is PAH awareness month. It seems fitting to reflect on my career choice to specialize in the treatment of

In Memoriam:  Greg Ahearn, MD

By Dr. Jeremy Feldman

The pulmonary hypertension community lost a Giant today.   I met Dr. Ahearn in the end of 2003.  He was leaving Duke

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives